Literature DB >> 21165572

The molecular contribution of TNF-α in the link between obesity and breast cancer.

Michael Weichhaus1, Iain Broom, Giovanna Bermano.   

Abstract

Obesity is a growing worldwide medical problem, as it pre-disposes the affected hosts to a number of severe diseases, including postmenopausal breast cancer. Obesity development is characterised, amongst others, by aberrant secretion of adipokines. White fat tissue infiltrating macrophages secrete tumour necrosis factor-α (TNF-α) so that its circulating levels correlate positively with body mass index (BMI). In the study presented here, the effect of TNF-α on cell proliferation, cell signalling pathway activation and cell cycle in two breast cancer cell lines and one breast epithelial cell lines was assessed to determine the contribution of TNF-α on breast cancer progression and aetiology, respectively. TNF-α acted differently on all three cell lines. In MDA-MB-231 breast cancer cells, cell proliferation and PI3-kinase activation were not affected, while MAP-kinase activation and cell cycle progression were decreased, with indications of increased apoptosis. This suggests a growth inhibitory function of TNF-α in these cells. In SK-BR-3 breast cancer cells, cell proliferation and cell signalling pathway activation increased, while cell cycle progression decreased, which contradictorily suggests both growth promoting and growth inhibiting properties of TNF-α on these cells. This makes TNF-α an unlikely candidate for a general contribution to the link between obesity and breast cancer progression, however, individual tumours may be responsive to a proliferative signal of TNF-α. In MCF-10A breast epithelial cells, cell proliferation and MAP-kinase activation increased, while cell cycle progression was unaffected. This suggests a strong proliferative response in these cells, suggesting the possibility that TNF-α may contribute to breast cancer aetiology as a novel link between obesity and increased risk of breast cancer development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21165572     DOI: 10.3892/or.2010.1099

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

Authors:  Eleanor Kane; Christine F Skibola; Paige M Bracci; James R Cerhan; Laura Costas; Karin Ekström Smedby; Elizabeth A Holly; Marc Maynadié; Anne J Novak; Tracy J Lightfoot; Stephen M Ansell; Alex G Smith; Mark Liebow; Mads Melbye; Lindsay Morton; Silvia de Sanjosé; Susan L Slager; Sophia S Wang; Yawei Zhang; Tongzhang Zheng; Eve Roman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-11       Impact factor: 4.254

2.  Increased serum tumor necrosis factor receptor-associated factor-6 expression in patients with non-metastatic triple-negative breast cancer.

Authors:  Cemil Bilir; Huseyin Engin; Murat Can; Sevili Likhan; Derya Demirtas; Fatih Kuzu; Taner Bayraktaroglu
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

Review 3.  Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review.

Authors:  Caroline Himbert; Mahmoud Delphan; Dominique Scherer; Laura W Bowers; Stephen Hursting; Cornelia M Ulrich
Journal:  Cancer Prev Res (Phila)       Date:  2017-09

Review 4.  Dietary fat in breast cancer survival.

Authors:  Nour Makarem; Urmila Chandran; Elisa V Bandera; Niyati Parekh
Journal:  Annu Rev Nutr       Date:  2013-05-22       Impact factor: 11.848

5.  Leptin inhibits proliferation of breast cancer cells at supraphysiological concentrations by inhibiting mitogen-activated protein kinase signaling.

Authors:  Michael Weichhaus; John Broom; Klaus Wahle; Giovanna Bermano
Journal:  Oncol Lett       Date:  2014-04-25       Impact factor: 2.967

Review 6.  Breast cancer microenvironment and obesity: challenges for therapy.

Authors:  Lauren E Hillers-Ziemer; Genevra Kuziel; Abbey E Williams; Brittney N Moore; Lisa M Arendt
Journal:  Cancer Metastasis Rev       Date:  2022-04-18       Impact factor: 9.237

7.  Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.

Authors:  Jihye Choi; Chan Sub Park; Min-Ki Seong; Hyesil Seol; Jae-Sung Kim; In-Chul Park; Woo Chul Noh; Hyun-Ah Kim
Journal:  J Breast Cancer       Date:  2019-12-31       Impact factor: 3.588

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.